Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ASRT

ASRT - Assertio Therapeutics Inc Stock Price, Fair Value and News

0.81USD0.00 (0.00%)Delayed as of 23 Feb 2024, 12:58 pm ET
Watchlist

Market Summary

USD0.810.00
Delayedas of 23 Feb 2024, 12:58 pm
0.00%

ASRT Stock Price

View Fullscreen

ASRT RSI Chart

ASRT Valuation

Market Cap

76.7M

Price/Earnings (Trailing)

-0.41

Price/Sales (Trailing)

0.45

EV/EBITDA

-0.22

Price/Free Cashflow

1.08

ASRT Price/Sales (Trailing)

ASRT Profitability

EBT Margin

-126.05%

Return on Equity

-96.44%

Return on Assets

-48.95%

Free Cashflow Yield

92.85%

ASRT Fundamentals

ASRT Revenue

Revenue (TTM)

169.4M

Rev. Growth (Yr)

4.14%

Rev. Growth (Qtr)

-13.09%

ASRT Earnings

Earnings (TTM)

-186.0M

Earnings Growth (Yr)

-6.8K%

Earnings Growth (Qtr)

-3.4K%

Breaking Down ASRT Revenue

52 Week Range

0.808.01
(Low)(High)

Last 7 days

6.3%

Last 30 days

-6.6%

Last 90 days

-25.4%

Trailing 12 Months

-81.5%

How does ASRT drawdown profile look like?

ASRT Financial Health

Current Ratio

1.62

Debt/Equity

0.2

Debt/Cashflow

1.82

ASRT Investor Care

Shares Dilution (1Y)

96.03%

Diluted EPS (TTM)

-1.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023162.2M168.0M169.4M0
2022120.7M130.5M139.2M156.2M
2021112.2M117.0M107.9M111.0M
2020198.7M167.9M137.1M106.3M
2019000229.5M

Tracking the Latest Insider Buys and Sells of Assertio Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 11, 2024
patel ajay
sold (taxes)
-13,105
0.8
-16,382
svp and cfo
Feb 11, 2024
schlessinger sam
sold (taxes)
-5,241
0.8
-6,552
svp, general counsel
Feb 11, 2024
schwichtenberg paul
sold (taxes)
-13,105
0.8
-16,382
see remarks
Feb 11, 2024
schlessinger sam
acquired
-
-
18,939
svp, general counsel
Feb 11, 2024
schwichtenberg paul
acquired
-
-
47,348
see remarks
Feb 11, 2024
patel ajay
acquired
-
-
47,348
svp and cfo
Nov 14, 2023
emany sravan kumar
acquired
-
-
177,570
-
Oct 01, 2023
schlessinger sam
acquired
-
-
19,404
svp, general counsel
Oct 01, 2023
schlessinger sam
sold (taxes)
-
-
-8,596
svp, general counsel
Sep 12, 2023
peisert daniel a.
sold
-92,432
2.9701
-31,121
president & ceo

1–10 of 50

Which funds bought or sold ASRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
8.27
-27,000
23,000
-%
Feb 16, 2024
Spouting Rock Asset Management, LLC
sold off
-100
-77,389
-
-%
Feb 15, 2024
ALETHEA CAPITAL MANAGEMENT, LLC
unchanged
-
-199,351
143,159
0.16%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
56.00
56.00
-%
Feb 15, 2024
TOWNSQUARE CAPITAL LLC
sold off
-100
-324,521
-
-%
Feb 15, 2024
State of Wyoming
new
-
40,352
40,352
0.01%
Feb 15, 2024
Main Street Group, LTD
new
-
133
133
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-62.00
-345,163
65,176
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-15,154
10,909
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
226
4,350,400
16,305,600
0.49%

1–10 of 42

Are Funds Buying or Selling ASRT?

Are funds buying ASRT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ASRT
No. of Funds

Unveiling Assertio Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
continental general insurance co
-
0
SC 13G/A
Feb 14, 2024
armistice capital, llc
6.13%
5,800,000
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
8.0%
7,619,440
SC 13G
Feb 13, 2024
vanguard group inc
5.15%
4,878,543
SC 13G
Jan 26, 2024
blackrock inc.
6.9%
6,574,483
SC 13G
May 05, 2023
continental general insurance co
6.7%
96,426
SC 13G
Jan 27, 2022
highbridge capital management llc
0%
0
SC 13G/A
Feb 16, 2021
d. e. shaw & co, l.p.
2.2%
2,321,422
SC 13G/A
Feb 11, 2021
renaissance technologies llc
6.08%
6,522,314
SC 13G/A
Feb 04, 2021
ci investments inc.
5.63%
6,258,862
SC 13G/A

Recent SEC filings of Assertio Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
4
Insider Trading
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
4
Insider Trading

Peers (Alternatives to Assertio Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
156.0B
46.5B
-3.76% -37.06%
-112.32
3.35
42.59% -114.62%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.58
2.9
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.1B
8.8B
-0.23% 18.85%
-5.25
0.35
7.79% -163.11%
2.5B
601.3M
-0.28% 70.16%
18.38
4.14
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
22.4M
84.1M
58.23% -28.98%
-1.05
0.22
2882.68% -145.15%
16.8M
111.1M
-6.33% -18.68%
-1.05
0.15
-10.43% 84.90%
2.4M
20.0M
-35.83% -91.10%
-0.17
0.12
137.71% 66.04%

Assertio Therapeutics Inc News

Latest updates
Yahoo Finance05 Feb 202408:00 am
Yahoo Finance04 Jan 202408:00 am
InvestorPlace6 months ago

Assertio Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Revenue-13.1%35,62740,99142,46650,35234,21235,13136,53833,32925,47225,37326,83930,17634,56520,61720,91738,03255,14757,203
Costs and Expenses823.7%263,89828,57137,82239,73027,77824,34024,97925,34719,53837,37419,33263,27241,24046,36937,549-65,28053,585
  S&GA Expenses25.2%21,00516,77116,90413,70411,90010,54310,63811,2649,01324,0408,32421,27227,60728,13127,314-36,11724,755
  R&D Expenses161.6%1,316503----------------
EBITDA Margin-393.8%-1.02*0.35*0.35*0.47*0.47*0.51*0.37*0.35*-0.02*-0.14*-0.43*-0.03*------
Interest Expenses---1,1226,798--2,3272,4372,4952,6052,6842,5983,0501,6048,674-13,87214,842
Income Taxes1200.0%50,7003,900-2,110-79,97521059371343446.00-300548-10,9951,050-9,4722,048--1,7151,141
Earnings Before Taxes-1956.3%-228,88512,330-5,5948,5784,3848,4279,7775,0413,783-14,4695,092-35,348-9,472-43,97143,278-1,616-12,464
EBT Margin-1175.2%-1.26*0.12*0.10*0.20*0.20*0.21*0.03*0.00*-0.38*-0.46*-0.75*-0.43*------
Net Income-3400.4%-279,5448,470-3,48488,5534,1747,8349,0644,6073,737-14,1694,544-24,353-10,522-34,49941,230-192,6263,331-13,605
Net Income Margin-288.8%-1.10*0.58*0.60*0.70*0.18*0.19*0.03*-0.01*-0.28*-0.38*-0.58*-0.26*------
Free Cashflow-85.9%2,57918,32722,44326,42310,04514,37727,3734,0784,654964-4,226-5,982------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-6.2%380405414414323322339327299312325303333346436527
  Current Assets38.5%18513413813212611712510311311912494.00104135-104
    Cash Equivalents9.6%77.0070.0069.0065.0065.0052.0061.0037.0059.0054.0061.0021.0035.0059.0010642.00
  Inventory127.0%43.0019.0016.0014.0014.0012.009.007.005.007.009.0012.0013.0025.00-3.00
  Net PPE-8.3%1.001.001.001.001.001.001.002.002.002.002.002.004.007.00-3.00
  Goodwill-20.00-----------9.009.00--
Liabilities24.0%187151164188188194227224202220220248257261365469
  Current Liabilities43.8%11479.0095.0095.0092.00116139135100117109133131134-185
  Long Term Debt1.6%39.0038.0038.0066.0066.0050.0061.0061.0066.0067.0072.0072.0077.0092.00-271
    LT Debt, Current---0.000.00---12.00---12.00---80.00
    LT Debt, Non Current1.6%39.0038.0038.0066.0066.0050.0061.0061.0066.0067.0072.0072.0077.0092.00-271
Shareholder's Equity-24.1%19325425122613512811210297.0092.0010556.0076.0085.0084.0058.00
  Retained Earnings-88.9%-594-314-323-319-408-412-420-429-433-437-423-427-403-393--399
  Additional Paid-In Capital38.3%787569574545543541532532531530529483480478-458
Shares Outstanding67.3%95.0057.0056.0048.0047.0046.0045.0045.0045.0045.0038.0028.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-86.1%2,57918,60122,71726,69710,04514,43027,4264,1314,654964-4,226-5,982-14,431-20,096-25,063---
  Share Based Compensation-15.4%1,8652,2052,4462,3882,4001,7349829498679577723,8861,5113,5931,934---
Cashflow From Investing689.5%4,144-703-105-25,784-371-16,114-404-18,525-----1.0063,766449,036---
Cashflow From Financing99.9%-10.00-16,326-18,950-7982,888-7,441-2,443-7,522-356-7,56944,473-7,969-10,234-90,240-360,107---

ASRT Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 35,627$ 34,212$ 119,084$ 105,884
Costs and expenses:    
Cost of sales7,0604,00917,29912,734
Research and development expenses1,31601,8190
Selling, general and administrative expenses21,00511,90054,68033,084
Change in fair value of contingent consideration(17,532)3,900(8,124)6,845
Amortization of intangible assets10,1847,96922,75224,438
Loss on impairment of intangible assets238,8310238,8310
Restructuring charges3,03403,0340
Total costs and expenses263,89827,778330,29177,101
(Loss) income from operations(228,271)6,434(211,207)28,783
Other (expense) income:    
Debt-related expenses00(9,918)0
Interest expense(752)(2,052)(2,625)(6,648)
Other gain13821,601453
Total other expense(614)(2,050)(10,942)(6,195)
Net (loss) income before income taxes(228,885)4,384(222,149)22,588
Income tax expense(50,659)(210)(52,409)(1,516)
Net (loss) income and comprehensive income(279,544)4,174(274,558)21,072
Net (loss) income and comprehensive income$ (279,544)$ 4,174$ (274,558)$ 21,072
Basic net (loss) income per share (in dollars per share)$ (3.42)$ 0.09$ (4.35)$ 0.45
Diluted net (loss) income per share (in dollars per share)$ (3.42)$ 0.08$ (4.35)$ 0.42
Shares used in computing diluted net (loss) income per share (in shares)81,71348,18063,06646,566
Shares used in computing diluted net (loss) income per share (in shares)81,71357,38663,06650,470
Product sales, net    
Revenues:    
Total revenues$ 35,137$ 34,279$ 116,989$ 105,258
Royalties and milestones    
Revenues:    
Total revenues4904731,9101,916
Other revenue    
Revenues:    
Total revenues$ 0$ (540)$ 185$ (1,290)

ASRT Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 76,888$ 64,941
Accounts receivable, net62,46745,357
Inventories, net42,71013,696
Prepaid and other current assets2,8958,268
Total current assets184,960132,262
Property and equipment, net804744
Intangible assets, net170,413197,996
Goodwill19,8560
Deferred tax asset080,202
Other long-term assets3,9952,709
Total assets380,028413,913
Current liabilities:  
Accounts payable19,0045,991
Accrued rebates, returns and discounts59,42449,426
Accrued liabilities22,06512,181
Long-term debt, current portion0470
Contingent consideration, current portion12,80026,300
Other current liabilities996948
Total current liabilities114,28995,316
Long-term debt38,86666,403
Contingent consideration16,10022,200
Other long-term liabilities17,9004,269
Total liabilities187,155188,188
Commitments and contingencies (Note 14)
Shareholders’ equity:  
Common stock, $0.0001 par value, 200,000,000 shares authorized; 94,553,009 and 48,319,838 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.95
Additional paid-in capital787,023545,321
Accumulated deficit(594,159)(319,601)
Total shareholders’ equity192,873225,725
Total liabilities and shareholders' equity$ 380,028$ 413,913
ASRT
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
 CEO
 WEBSITEwww.assertiotx.com
 EMPLOYEES30

Assertio Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Assertio Therapeutics Inc? What does ASRT stand for in stocks?

ASRT is the stock ticker symbol of Assertio Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assertio Therapeutics Inc (ASRT)?

As of Thu Feb 22 2024, market cap of Assertio Therapeutics Inc is 76.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers.

What is the fair value of ASRT stock?

You can check ASRT's fair value in chart for subscribers. The fair value of Assertio Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assertio Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assertio Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ASRT is over valued or under valued. Whether Assertio Therapeutics Inc is cheap or expensive depends on the assumptions which impact Assertio Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASRT.

What is Assertio Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ASRT's PE ratio (Price to Earnings) is -0.41 and Price to Sales (PS) ratio is 0.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assertio Therapeutics Inc's stock?

In the past 10 years, Assertio Therapeutics Inc has provided -0.334 (multiply by 100 for percentage) rate of return.